The present study elucidates the possible roles of gymnemagenin as ligand binding with at least 7 of 15 potential protein targets associated with glucose metabolism.

The ADMET properties have been predicted for gymnemagenin which was shown to be non-carcinogenic, non-toxic and biodegradable making it fit for human use.

The results of this study not only demonstrate the drug likeliness of gymnemagenin but also provide possible scientific indication of its probable modes of action.

The results were found comparable with two clinically used anti-diabetic compounds, viz., repaglinide and sitagliptin.

Our study underscores the importance of gymnemagenin which could be developed as a potent anti-diabetic drug.